Amlodipine inhibits cell proliferation via PKD1-related pathway

Biochemical and Biophysical Research Communications

Volumn 369, Issue 2, 2008, Pages 376-381

  Ohba, Takayoshi ^a   Watanabe, Hiroyuki ^a   Murakami, Manabu ^a   Radovanovic, Milena ^a   Iino, Kenji ^a   Ishida, Masaru ^a   Tosa, Shinya ^a   Ono, Kyoichi ^a   Ito, Hiroshi ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Amlodipine; hCASMC; PKD1

Indexed keywords

AMLODIPINE; CYCLIN DEPENDENT KINASE INHIBITOR 1; JANUS KINASE 2; POLYCYSTIN 1;

ARTERY MUSCLE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY; ENZYME ASSAY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; APOPTOSIS; CELL PROLIFERATION; CELLS, CULTURED; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MYOCYTES, SMOOTH MUSCLE; SIGNAL TRANSDUCTION; TRPP CATION CHANNELS;

EID: 40849139139     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.02.075     Document Type: Article

References (24)

1. Newby A.C., and George S.J. Proliferation, migration, matrix turnover and death of smooth muscle cells in native coronary and vein graft atherosclerosis. Curr. Opin. Cardiol. 11 (1996) 574-582
2. Reidy M., Fingerle J., and Lindner V. Factors controlling the development of arterial lesions after injury. Circulation 86 (1993) 43-46
3. Stepien O., Gogusev J., Zhu D.L., Iouzalen L., Herembert T., Drueke T.B., and Marche P. Amlodipine inhibition of serum-, thrombin-, or fibroblast growth factor-induced vascular smooth-muscle cell proliferation. J. Cardiovasc. Pharmacol. 31 (1998) 786-793
4. Mason R.P., Marche P., and Hintze T.H. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 2155-2163
5. Ziesche R., Petkov V., Lambers C., Erne P., and Block L.H. The calcium channel blocker amlodipine exerts its anti-proliferative action via p21(Waf1/Cip1) gene activation. FASEB J. 18 (2004) 1516-1523
6. Pitt B., Byington R.P., Furberg C.D., Hunninghake D.B., Mancini G.B., Miller M.E., and Riley W. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 102 (2000) 1503-1510
7. Nissen S.E., Tuzcu E.M., Libby P., Thompson P.D., Ghali M., Garza D., Berman L., Shi H., Buebendorf E., and Topol E.J. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292 (2004) 2217-2225
8. Gabow P. Autosomal dominant polycystic kidney disease. N. Engl. J. Med. 329 (1993) 323-342
9. Nilius B., Owsianik G., Voets T., and Peters J.A. Transient receptor potential cation channels in disease. Physiol. Rev. 87 (2007) 165-217
10. Bhunia A.K., Piontek K., Boletta A., Liu L., Qian F., Xu P.N., Germino F.J., and Germino G.G. PKD1 induces p21(waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2. Cell 109 (2002) 157-168
11. Hanaoka K., Qian F., Boletta A., Bhunia A.K., Piontek K., Tsiokas L., Sukhatme V.P., Guggino W.B., and Germino G.G. Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents. Nature 408 (2000) 990-994
12. 2+ channel blocker, in human epidermoid carcinoma A431 cells. Biochem. Pharmacol. 73 (2007) 943-953
13. Murakami M., Ohba T., Xu F., Shida S., Satoh E., Ono K., Miyoshi I., Watanabe H., Ito H., and Iijima T. Genomic organization and functional analysis of murine PKD2L1. J. Biol. Chem. 280 (2005) 5626-5635
14. Li X., Luo Y., Starremans P.G., McNamara C.A., Pei Y., and Zhou J. Polycystin-1 and polycystin-2 regulate the cell cycle through the helix-loop-helix inhibitor Id2. Nat. Cell Biol. 27 (2005) 1202-1212
15. Bromberg J.F., Fan Z., Brown C., Mendelsohn J., and Darnell Jr. J.E. Epidermal growth factor-induced growth inhibition requires Stat1 activation. Cell Growth Differ. 9 (1998) 505-512
16. Darnell Jr. J.E. STATs and gene regulation. Science 277 (1997) 1630-1635
17. Leaman D.W., Leung S., Li X., and Stark G.R. Regulation of STAT-dependent pathways by growth factors and cytokines. FASEB J. 10 (1996) 1578-1588
18. Leonard W.J., and O′Shea J.J. Jaks and STATs: biological implications. Annu. Rev. Immunol. 16 (1998) 293-322
19. Takahashi Y., Watanabe H., Murakami M., Ohba T., Radovanovic M., Ono K., Iijima T., and Ito H. Involvement of transient receptor potential canonical 1 (TRPC1) in angiotensin II-induced vascular smooth muscle cell hypertrophy. Atherosclerosis (2007) (Epub ahead of print)
20. Puri S., Magenheimer B.S., Maser R.L., Ryan E.M., Zien C.A., Walker D.D., Wallace D.P., Hempson S.J., and Calvet J.P. Polycystin-1 activates the calcineurin/NFAT (nuclear factor of activated T-cells) signaling pathway. J. Biol. Chem. 279 (2004) 55455-55464
21. R Martinez J., and Grantham J.J. Polycystic kidney disease: etiology, pathogenesis, and treatment. Dis. Mon. 41 (1995) 693-765
22. Christ M., Bechtel U., Schnaack S., Theisen K., and Wehling M. Aneurysms of coronary arteries in a patient with adult polycystic kidney disease: arteriosclerosis or involvement by the primary disease?. Clin. Invest. 71 (1993) 150-152
23. Adubofour K., Sidaway L., and Glatter T. Coronary artery aneurysms in association with adult polycystic kidney disease. Am. Heart J. 127 (1994) 1411-1413
24. Hadimeri H., Lamm C., and Nyberg G. Coronary aneurysms in patients with autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. (1998) 837-841